(Q47913432)

6 February 2018

title

Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity (English)

1 reference

6 February 2018

author name string

C D Rudulier

series ordinal

1

1 reference

6 February 2018

M Larché

series ordinal

2

1 reference

6 February 2018

D Moldaver

series ordinal

3

1 reference

6 February 2018

publication date

30 November 2015

1 reference

6 February 2018

published in

Allergy

1 reference

6 February 2018

volume

71

1 reference

6 February 2018

issue

3

1 reference

6 February 2018

page(s)

283-285

1 reference

6 February 2018

Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling

cites work

1 reference

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

The potential of biologics for the treatment of asthma

21 January 2018

1 reference

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

21 January 2018

1 reference

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25

21 January 2018

1 reference

In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

21 January 2018

1 reference

In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy

21 January 2018

1 reference

IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R

21 January 2018

1 reference

Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells

21 January 2018

1 reference

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

21 January 2018

1 reference

Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

21 January 2018

1 reference

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

21 January 2018

1 reference

Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept

21 January 2018

1 reference

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

21 January 2018

1 reference

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

21 January 2018

1 reference

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ALL.12816

1 reference

6 February 2018

1 reference

6 February 2018